The potential reassessment of cannabinoids, particularly at the federal level, is generating considerable buzz within the market. A shift away from Schedule I status, often regarded as outdated and hindering progress, https://ezmarkbookmarks.com/story20858014/pot-rescheduling-a-growth-catalyst